www.bjcancer.com

A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status

WJ Louwman^{*,1,2}, MJ Aarts¹, S Houterman³, FJ van Lenthe², JWW Coebergh^{1,2} and MLG Janssen-Heijnen^{1,2}

¹Comprehensive Cancer Centre South (IKZ), Eindhoven Cancer Registry, PO Box 231, Eindhoven 5600 AE, The Netherlands; ²Department of Public Health, Erasmus University Medical Center Rotterdam, PO Box 2040, Rotterdam 3000 CA, The Netherlands; ³MMC Academy, Máxima Medical Center, PO Box 7777, Veldhoven 5500 MB, The Netherlands

BACKGROUND: Comorbidity and socioeconomic status (SES) may be related among cancer patients.

METHOD: Population-based cancer registry study among 72 153 patients diagnosed during 1997-2006.

RESULTS: Low SES patients had 50% higher risk of serious comorbidity than those with high SES. Prevalence was increased for each cancer site. Low SES cancer patients had significantly higher risk of also having cardiovascular disease, chronic obstructive pulmonary diseases, diabetes mellitus, cerebrovascular disease, tuberculosis, dementia, and gastrointestinal disease. One-year survival was significantly worse in lowest vs highest SES, partly explained by comorbidity.

CONCLUSION: This illustrates the enormous heterogeneity of cancer patients and stresses the need for optimal treatment of cancer patients with a variety of concomitant chronic conditions.

British Journal of Cancer (2010) 103, 1742–1748. doi:10.1038/sj.bjc.6605949 www.bjcancer.com

Published online 26 October 2010

© 2010 Cancer Research UK

Keywords: socioeconomic status; comorbidity; chronic disease; survival

People of a lower socioeconomic status (SES) generally have poorer health status and higher mortality than people of higher SES (Jemal et al, 2008; Mackenbach et al, 2008), also with respect to cancer, with in general higher incidence rate of all cancers combined among people from lower socioeconomic groups (Dalton et al, 2008). A differential distribution of known risk factors for specific neoplasms between SES groups seems a likely explanation for the above inequalities. For example, the prevalence of smokers has become higher among lower classes (Lahelma et al, 1997; Stronks et al, 1997), probably resulting in higher rates of cancer of the lung, larynx, mouth, pharynx, oesophagus, and bladder (Siemiatycki et al, 1995; Stellman and Resnicow, 1997; Tyczynski et al, 2003). However, smoking is not only related to cancer but also to chronic obstructive pulmonary diseases (COPD) and cardiovascular diseases (Doll et al, 1994). Hence, the high prevalence of comorbidity among lung cancer patients (Janssen-Heijnen et al, 1998). Socioeconomic status may thus be associated with comorbidity among cancer patients. Thus, medical doctors are presented with a heterogeneous group of cancer patients, for whom appropriate individual treatment must be chosen, taking concomitant conditions into account (Ayanian et al, 2003; Lash et al, 2003; Janssen-Heijnen et al, 2004; Lemmens et al, 2005; Louwman et al, 2005; van Spronsen et al, 2005).

We studied in a large population-based group of cancer patients the prevalence of comorbidity according to SES, not only by number of concomitant diseases, but also for specific diseases that affect patients with the various tumour sites.

MATERIALS AND METHODS

The Eindhoven Cancer Registry records data on all patients newly diagnosed with cancer in the south of the Netherlands (2.4 million inhabitants, 15% of the Dutch population); it also records serious comorbidity according to an adaptated list (Charlson et al, 1987). Chronic obstructive pulmonary diseases, cardio- and cerebrovascular diseases, peripheral arterial disease, other malignancies, and diabetes mellitus, connective tissue diseases, rheumatoid arthritis, kidney, bowel, and liver diseases, dementia, tuberculosis and other chronic infections were also recorded. For most analyses peripheral arterial disease was included in the cardiovascular diseases, although gastrointestinal diseases were grouped (gastric diseases, Crohn's disease, ulcerative colitis, liver cirrhosis, and hepatitis). Comorbidity was defined as life-shortening disease that was present at the time of cancer diagnosis and/or received treatment or surveillance. Trained registry personnel actively collect data on diagnosis, staging, and treatment from the medical records after notification by pathologists and medical registration offices. Previous admissions, letters from and to general practitioners and other specialists, the medical history and preoperative screening were used as sources.

Patients with cancer of the oesophagus, stomach, colon or rectum, pancreas, lung, melanoma, breast, cervix uteri, corpus uteri, ovary, prostate, bladder, kidney, and non-Hodgkin's lymphoma (NHL), newly diagnosed between 1997 and 2006 $(n = 72\,153)$, were included in this study; cancers diagnosed at autopsy (n = 369) were excluded.

Statistics Netherlands developed an indicator of SES, using individual fiscal data on the economic value of the home and household income, and is provided at aggregated level

^{*}Correspondence: Dr WJ Louwman; E-mail: research@ikz.nl Revised 17 August 2010; accepted 15 September 2010; published online 26 October 2010

WJ Louwman et al

 Table I
 Description of all cancer patients diagnosed with selected tumours between 1997 and 2006 in the Eindhoven Cancer Registry

n % n % n % Turnour localisation Oesophagus 1079 3 398 1 1477 Stomach 1723 5 1032 3 2755 Colorectal 6815 19 6014 17 12.829 Pancreas 907 2 849 2 1756 Lung 9354 26 3591 10 12.945 Melanoma 1405 4 1899 5 3304 Breast — 14.859 41 14.859 1 Cervix uteri — 725 2 725 Corpus uteri — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 1413 4 3259	n
Tumour localisationOesophagus1079339811477Stomach17235103232755Colorectal68151960141712.829Pancreas907284921756Lung93542635911012.945Melanoma14054189953304Breast—14.8594114.859Cervix uteri—7252725Corpus uteri—212862128Ovary—154041540Prostate998727—9987Kidney1201380622007Urinary bladder2306667922985Non-Hodgkin's lymphoma18465141343259Age45115633884115040455966241810.5782917.02	
Oesophagus 1079 3 398 1 1477 Stomach 1723 5 1032 3 2755 Colorectal 6815 19 6014 17 12.829 Pancreas 907 2 849 2 1756 Lung 9354 26 3591 10 12.945 Melanoma 1405 4 1899 5 3304 Breast — 14.859 41 14.859 1 Cervix uteri — 725 2 725 Corpus uteri — 2128 6 2128 Ovary — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 1413 4 3259 Age <t< td=""><td></td></t<>	
Stomach 1723 5 1032 3 2755 Colorectal 6815 19 6014 17 12 829 Pancreas 907 2 849 2 1756 Lung 9354 26 3591 10 12 945 Melanoma 1405 4 1899 5 3304 Breast — 14 859 41 14 859 1 Cervix uteri — 725 2 725 Corpus uteri — 2128 6 2128 Ovary — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	1079
Colorectal 6815 19 6014 17 12829 Pancreas 907 2 849 2 1756 Lung 9354 26 3591 10 12945 Melanoma 1405 4 1899 5 3304 Breast— 14859 41 14859 41Cervix uteri— 725 2 725 Corpus uteri— 2128 6 2128 Ovary— 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259 Age $45 = 59$ 6624 18 10578 29 17.02	1723
Pancreas 907 2 849 2 1756 Lung 9354 26 3591 10 12945 Melanoma 1405 4 1899 5 3304 Breast — 14859 41 14859 1 Cervix uteri — 725 2 725 Corpus uteri — 2128 6 2128 Ovary — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	6815
Lung 9354 26 3591 10 12945 Melanoma 1405 4 1899 5 3304 Breast — 14859 41 14859 2 Cervix uteri — 725 2 725 Corpus uteri — 2128 6 2128 Ovary — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	907
Melanoma 1405 4 1899 5 3304 Breast 14859 41 14859 Cervix uteri 725 2 725 Corpus uteri 2128 6 2128 Ovary 1540 4 1540 Prostate 9987 27 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	9354
Breast — 14859 41 14859 Cervix uteri — 725 2 725 Corpus uteri — 2128 6 2128 Ovary — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	1405
Cervix uten 725 2 725 Corpus uteri 2128 6 2128 Ovary 1540 4 1540 Prostate 9987 27 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	
Corpus uteri — 2128 6 2128 Ovary — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	
Ovary — 1540 4 1540 Prostate 9987 27 — 9987 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259 Age	_
Prostate 7767 27 — 7787 Kidney 1201 3 806 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	
Non-Hodgkin's lymphoma 1201 3 606 2 2007 Urinary bladder 2306 6 679 2 2985 Non-Hodgkin's lymphoma 1846 5 1413 4 3259	770/
Age	2304
Age <45 156 3 3884 1 5040 45_59 6624 8 10578 29 17202	2300 ma 1844
Age <45 156 3 3884 1 5040 45_59 6624 18 10578 29 17.202	ina ioto
<45 II56 3 3884 II 5040 45_59 6624 I8 I0578 29 I7202	
45-59 6674 18 10578 79 17707	1156
	6624
	18 984
>75 7637 27 6327 23 16166	7037
SES	
Low 9518 26 9953 28 194/1	9518
Intermediate 14 309 39 13 824 38 28 133	14309
High 10812 30 9/41 2/ 20553	10812
Institution 1569 4 2032 6 3601	1565
Unknown 415 1 383 1 798	415
Comorbidity	
Number of concomitant diseases	diseases
0 10688 29 14826 41 25514	10688
I 10775 29 9353 26 20128 1	10 / /5
>2 10992 30 /050 20 18042	10.992
Unknown 4168 11 4704 13 8872	4168
Concomitant disease ^a	
Previous cancer 4460 12 3565 10 7977	4460
Cardiovascular disease 8353 23 3854 11 12127	se 8353
Peripheral arterial disease 3445 9 1358 4 4/6/	sease 3445
COPD 534/ 15 26/4 / /994	534/
Hypertension 636/ 1/ /184 20 13462	6367
Diabetes mellitus 3586 10 3482 10 7026	3586
Cerebrovascular disease 1/54 5 1044 3 2/79 Telesevelasie	ase 1/54
1000000000000000000000000000000000000	553
Central nervous system 221 I 554 I 568 Controlintactinal disease 2629 7 1294 4 2000	221
Odsu unitesultati uisease 2027 / 1274 4 3900 Othor dispases 925 3 1078 2 1907	15C 2025
Total 36623 50 35 933 50 72 556 1	36.623

Abbreviations: COPD = chronic obstructive pulmonary diseases; SES = socioeconomic status. ^aPatients may suffer from more than one condition. ^bDementia in 96% of these patients.

for each postal code (covering an average of 17 households). Socioeconomic status was categorised as low (deciles 1–3), medium (deciles 4–7), or high social class (deciles 8–10), and a separate class for postal codes for a long-term care providing institution (such as a nursing home; van Duijn and Keij, 2002). We calculated the distribution of cancer patients across socio-economic strata according to tumour localisation, also by gender and age. Patients for whom the SES was unknown (n = 766, 1%) or for whom the postal code included a care providing institution (n = 3569, 5%), as well as those with unknown comorbidity (n = 8399, 12%) were excluded from the analyses of SES and comorbidity. Differences in distribution were tested with the

	Males				Females			
	<70		70+		<70		70+	
Tumour localisation	No. of patients	% low SES						
Oesophagus	589	23	342	37	170	30	161	43
Stomach	767	26	719	37	386	31	465	44
Colorectal	3176	21	2662	32	2266	24	2630	40
Pancreas	433	24	339	36	325	28	374	44
Lung	4498	29	3827	38	2226	35	923	50
Melanoma	563	15	169	33	729	16	194	43
Breast			_		9070	21	3094	42
Cervix uteri			_		476	37	120	43
Corpus uteri	_		_	_	1189	25	576	42
Ovary	_		_	_	875	23	438	42
Prostate	3930	20	4149	30	_		_	_
Kidney	639	22	392	32	372	31	300	41
Urinary	855	25	1027	33	216	32	308	40
bladder								
Non-Hodgkin's lymphoma	1060	21	575	31	703	25	514	42
Total of these sites	16510	23	14201	34	19003	24	10097	42

 Table 2
 Distribution of cancer patients newly diagnosed in 1997–2006

according to gender, age and socioeconomic status (SES)

 χ^2 test. Logistic regression analyses of the odds of having a specific concomitant disease were performed age- and gender-adjusted for all tumour sites combined, and according to tumour site for four concomitant diseases separately; cardiovascular disease, COPD, diabetes mellitus, and gastrointestinal disease. Statistical significance of an overall effect of SES on the prevalence of a specific condition was tested using the χ^2 -likelihood ratio test. Crude 1-year survival rates were calculated for all studied tumours combined and for the most important tumour sites separately. Cox's regression models were used to compute multivariate rates (hazard ratio = HR) and 95% confidence intervals (95% CI). The relative contribution (%) of adding comorbidity to the model was calculated as follows: ((HR model A-HR model B)/(HR model A-1) × 100, where A is the basic model (age- and genderadjusted) and in model B comorbidity is added to model A. All statistical analyses were performed using SAS V9.12 (SAS Institute Inc., Cary, NC, USA).

RESULTS

Male cancer patients were older than female patients (Table 1), the median age being 69 and 64 years, respectively (P < 0.0001). At the time of the diagnosis of the cancer 71% of male and 58% of female cancer patients had at least one concomitant disease. The most frequent concomitant condition for males with cancer was cardiovascular disease (23%), for women hypertension (20%), among cancer patients older than 70 the prevalence of these diseases was 34% and 31%, respectively. In the subgroup of cancer patients with two or more concomitant diseases, the most frequent combination of diseases among males was cardiovascular disease with hypertension (14%) and in females diabetes with hypertension (21%).

The proportion of patients by SES varied for the different tumour sites (Table 2). Patients under age 70 with stomach, lung, bladder, or cervical cancer more often had low SES. High SES was more frequent among patients with melanoma or breast, colorectal, or prostate cancer in this age group.

Among patients aged 70 + with cancer of the oesophagus, stomach, or lung, low SES was clearly over-represented. High SES was more frequent among patients with prostate cancer or NHL.

For all tumour localisations the proportion of patients without comorbidity was highest in the high SES group (Figure 1).





Figure I Number of concomitant diseases among cancer patients diagnosed in 1997–2006 in the Southeastern Netherlands. *Distribution of number of concomitant diseases significantly different from the highest socioeconomic status category.

A gradient towards more concomitant conditions appeared in lower SES groups (P < 0.001), which had a significantly higher risk of cardiovascular disease (OR_{low ν s high SES = 1.4, 95% CI: 1.3-1.5), COPD (OR = 1.8 (1.7-1.9)), diabetes mellitus (OR = 1.5}

(1.4–1.6)), cerebrovascular disease (OR = 1.5 (1.4–1.7)), tuberculosis (OR = 1.3 (1.1–1.6)), dementia (OR = 1.3 (1.0–1.8)), gastrointestinal disease (OR = 1.5 (1.4–1.6)), and two or more concomitant conditions (OR = 1.8 (1.7–1.9)) in addition to their

Epidemiology

 Table 3
 Risk of specific concomitant diseases according to SES adjusted for age and gender among cancer patients diagnosed in 1997–2006

	SES					
Concomitant disease	Low	Intermediate	High	P ^a		
Previous cancer Cardiovascular disease COPD Hypertension Diabetes mellitus Cerebrovascular disease Tuberculosis Central nervous system Gastrointestinal Other L or more concomitant disease	1.01 1.42 ^b 1.81 ^b 0.98 1.52 ^b 1.53 ^b 1.34 ^b 1.34 ^b 1.48 ^b 1.22 ^b 1.50 ^b	0.99 1.23 ^b 1.37 ^b 1.03 1.32 ^b 1.27 ^b 1.17 1.05 1.27 ^b 1.10 1.24 ^b	1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00	0.7 0.0001 0.2 0.0001 0.001 0.001 0.01 0.05 0.0001 0.01 0.		
2 or more concomitant diseases	1.80 ^b	1.36 ^b	1.00	0.0001		

Abbreviations: COPD = chronic obstructive pulmonary diseases; SES = socio-economic status. ^aP for overall effect of SES (χ^2 -likelihood ratio). ^bConfidence interval does not include 1.00.

cancer (Table 3). The risk of having cancer and also at least one other serious concomitant disease was 50% higher in the low SES than in the high SES group (OR = 1.5 (1.4-1.6)).

For four concomitant conditions we stratified by tumour localisation (Figure 2). The risk of cardiovascular disease among low compared with high SES patients was significantly higher (1.4–1.6 times) for patients with stomach, colorectal, lung, breast, prostate, and bladder cancer. The risk of COPD was elevated among low SES patients with cancer of the stomach, colorectum, pancreas, lung, breast, corpus uteri, prostate, and kidney (OR's ranging from 1.4 to 2.2). The risk of diabetes mellitus was highest among people from low SES with breast cancer (OR = 2.0 (1.2–2.4)) and the risk of gastrointestinal diseases was highest among patients with oesophageal cancer (OR = 2.0 (1.2–3.4)).

Crude 1-year survival of cancer patients from lower SES was worse compared with the highest SES for all tumour sites combined and for the major sites separately (Table 4). The ageadjusted risk of death was significantly elevated for both men (HR_{low vs high SES} = 1.40, 95% CI: 1.3-1.4) and women (HR 1.40 (1.3-1.5)). Adding comorbidity to the model reduced HR to 1.35



Figure 2 Risk of four concomitant diseases among cancer patients with the lowest socioeconomic status (SES) compared with those with the highest SES (= reference, 1.00) according to tumour localisation with adjustment for age and gender. *95% confidence interval does not include 1.00; # No reliable estimate because <5 cases in reference category.

WJ Louwman et al

1746

Table 4 Crude survival, risk of death, and contribution of comorbidity to risk of death according to tumour site and SES among cancer patients diagnosed in 1997–2006

	I-year survival rate (%)			Model A ^a	Model B ^a	Deletius contuibution
	Low SES	Inter-mediate	High SES	HR ^c (95% CI)	HR ^c (95% CI)	comorbidity ^b
Males						
Colorectum	72	78	78	1.13 (1.0-1.3)	1.10 (1.0-1.3)	23%
Lung	36	39	41	1.11 (1.0-1.2)	1.11 (1.0-1.2)	0%
Prostate	90	94	95	1.47 (1.2-1.8)	1.36 (1.1–1.7)	22%
Total ^d	59	66	70	1.40 (1.3–1.5)	1.35 (1.3–1.4)	12%
Females						
Colorectum	74	78	79	1.09 (0.9-1.3)	1.06 (0.9-1.2)	33%
Lung	41	42	46	1.09 (1.0-1.2)	1.09 (1.0-1.2)	0%
Breast	94	97	98	1.68 (1.3-2.2)	1.56 (1.2-2.0)	18%
Total ^d	74	81	84	1.40 (1.3–1.5)	1.34 (1.3–1.4)	15%

^aModel A: adjusted for age, Model B: adjusted for age and the presence of concomitant diseases (yes vs no). ^b((HR model A–(HR model A+comorbidity))/(I–HR model A)) \times 100. ^cHazard Ratio (HR) of lowest socioeconomic status (SES) group compared with highest (=reference). ^dAll studied sites combined (oesophagus, stomach, colorectum, pancreas, lung, melanoma, breast, cervix uteri, corpus uteri, ovary, prostate, kidney, urinary bladder, non-Hodgkin's lymphoma).

for men and 1.34 for women. The relative contribution of comorbidity in explaining the inequality in 1-year survival varied from 0% for lung cancer to 33% among female colorectal cancer patients.

DISCUSSION

To our knowledge, this is the first large population-based study to demonstrates the impact of SES on the prevalence of concomitant diseases among cancer patients, with increased prevalence of comorbidity in lower socioeconomic strata for each type of cancer. Cancer patients with low SES had a 50% higher risk of suffering from at least one other serious disease compared with those with high SES. The prevalence of comorbidity was significantly higher with newly diagnosed cancer of lower compared with higher SES for all 14 cancer sites studied. The diseases significantly related to SES among cancer patients were cardiovascular disease, COPD, diabetes mellitus, cerebrovascular disease, tuberculosis, diseases of the central nervous system, and gastrointestinal disease. Although both the prevalence of comorbidity and the proportional distribution of SES vary significantly among tumour types, the gradient of more comorbidity from high to low SES was apparent among all tumour types.

Smoking is probably responsible for the higher risk of cardiovascular disease, COPD, and cerebrovascular disease among low SES groups (Doll et al, 1994; Stellman and Resnicow, 1997). This is confirmed by the higher prevalence of those diseases among patients with smoking-related tumours: cancers of the stomach, lung, bladder, and kidney (Janssen-Heijnen et al, 1998; Koppert et al, 2004). Diabetes was more frequent among low SES for patients with cancers of the colorectum, pancreas, lung, breast, corpus uteri or prostate, or melanoma or NHL. Diabetes has been linked to pancreas cancer (Jain et al, 1991; Kalapothaki et al, 1993) either as a risk factor or as the clinical manifestation of the cancer itself (Warshaw and Fernandez-del Castillo, 1992). Diabetes has also been associated with an increased risk for breast (Xue and Michels, 2007), endometrial (Parazzini et al, 1991), and colorectal cancer (Polednak, 2006) probably because of a relation with obesity (Reeves et al, 2007). Substantial evidence exists for the association of obesity with low SES (Sobal and Stunkard, 1989; Wardle et al, 2002; McLaren, 2007).

The prevalence of gastrointestinal diseases was highest for low SES patients with oesophageal, colorectal, lung, breast, prostate or kidney cancer, or NHL. Oesophageal cancer has also been associated with gastrointestinal diseases (Koppert *et al*, 2004). A lower consumption of vegetables, fruit, and fibres, which may protect from oesophageal (Tzonou *et al*, 1996; Terry *et al*, 2001b) and colorectal cancer (Pietinen *et al*, 1999; Michels *et al*, 2000; Voorrips *et al*, 2000; Terry *et al*, 2001a; Bueno-de-Mesquita *et al*, 2002; Flood *et al*, 2002), has been reported among lower SES (Wallstrom *et al*, 2000; Hulshof *et al*, 2003; Wardle and Steptoe, 2003).

We used an indicator of SES based on the postal code of a residential area. This aggregate covers a very small geographical area, and thus represents a reliable approximation of individual SES. Furthermore, routinely collected income tax data (no questionnaires or interviews) have been found to provide reliable estimates of household income. Previous studies have proven that socioeconomic differences based on neighbourhood data tend to reflect such differences well at the individual level (Bos *et al*, 2000, 2001; Smits *et al*, 2001). Furthermore, this objective measure of SES is also applicable to older women (born before 1955), whose occupation or education does not always properly reflect their social class (Berkman and Macintyre, 1997).

Previously, we found that patients with comorbidity were often treated less aggressively, if alternative treatment strategies were available. Except for patients with a tumour with poor survival, comorbidity has an independent prognostic effect (Janssen-Heijnen et al, 2005). This negative impact of comorbidity on survival of cancer might have several mechanisms: the increased risk of death due to the comorbid condition itself, more contra-indications for the cancer treatment, more indications for dose reduction and a higher rate of treatment-related complications such as infections and cardiovascular events. In several of our recent studies, the adverse effects of comorbidity on survival appeared to be independent of treatment, so less aggressive treatment could not (fully) account for the observed differences in survival between patients with and without comorbidity (Post et al, 2001; Lemmens et al, 2005; Louwman et al, 2005; van Spronsen et al, 2005; Houterman et al, 2006). As SES represents a combination of lifestyle, health, and risk of suboptimal treatment, cancer patients with comorbidity could also (partly) explain the poorer prognosis. Although an in-depth study remains necessary to reveal whether stage at diagnosis and treatment contributed to the SES gradient in survival, also for longer survival periods, our preliminary analyses demonstrated a clear gradient in 1-year survival rates, which could partly be attributed to comorbidity.

Our study shows considerable variation in comorbidity by tumour type and a higher risk of concomitant disease among patients from lower SES. Given the aetiology of the type of tumours as well as the aetiology of the concomitant diseases that occur more frequently among patients from low SES background, a lot can probably be gained from preventive measures related to lifestyle (such as smoking and obesity). Considering survival is worse for patients of low SES, our

REFERENCES

- Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, O'Connor LC, West DW, Allen ME, Wolf RE, Wright WE (2003) Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21: 1293-1300
- Berkman LF, Macintyre S (1997) The measurement of social class in health studies: old measures and new formulations. *IARC Sci Publ* **138**: 51-64
- Bos V, Kunst AE, Mackenbach JP (2000) Nationale gegevens over sociaaleconomische sterfteverschillen op basis van informatie over kleine geografische eenheden. Verslag aan de programmacommissie Sociaaleconomische gezondheidsverschillen II. Instituut Maatschappelijke Gezondheidszorg, Erasmus Universiteit: Rotterdam
- Bos V, Kunst AE, Mackenbach JP (2001) De omvang van sociaaleconomische sterfteverschillen gemeten op buurtniveau: vergelijking met schattingen op basis van informatie op individueel niveau. In Sociaal-economische gezonheidsverschillen: Van verklaren naar verkleinen, Stronks K (ed) Vol. 5, pp 8-20. Zon/MW: Den Haag
- Bueno-de-Mesquita HB, Ferrari P, Riboli E (2002) Plant foods and the risk of colorectal cancer in Europe: preliminary findings. *IARC Sci Publ* **156**: 89-95
- Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* **40**: 373–383
- Dalton SO, Schuz J, Engholm G, Johansen C, Kjaer SK, Steding-Jessen M, Storm HH, Olsen JH (2008) Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994–2003: summary of findings. *Eur J Cancer* 44(14): 2074–2085
- Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years' observations on male British doctors. *Br Med J* **309:** 901-911
- Flood A, Velie EM, Chaterjee N, Subar AF, Thompson FE, Lacey Jr JV, Schairer C, Troisi R, Schatzkin A (2002) Fruit and vegetable intakes and the risk of colorectal cancer in the Breast Cancer Detection Demonstration Project follow-up cohort. Am J Clin Nutr 75: 936-943
- Houterman S, Janssen-Heijnen ML, Hendrikx AJ, Berg HA, Coebergh JW (2006) Impact of comorbidity on treatment and prognosis of prostate cancer patients: A population-based study. *Crit Rev Oncol Hematol* 58: 60-67
- Hulshof KF, Brussaard JH, Kruizinga AG, Telman J, Lowik MR (2003) Socio-economic status, dietary intake and 10 y trends: the Dutch National Food Consumption Survey. *Eur J Clin Nutr* **57**: 128-137
- Jain M, Howe GR, St Louis P, Miller AB (1991) Coffee and alcohol as determinants of risk of pancreas cancer: a case-control study from Toronto. Int J Cancer 47: 384-389
- Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. *Crit Rev Oncol Hematol* **55:** 231-240
- Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW (1998) Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. *Lung Cancer* 21: 105-113
- Janssen-Heijnen ML, Smulders S, Lemmens VE, Smeenk FW, van Geffen HJ, Coebergh JW (2004) Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. *Thorax* **59:** 602-607
- Jemal A, Thun MJ, Ward EE, Henley SJ, Cokkinides VE, Murray TE (2008) Mortality from leading causes by education and race in the United States, 2001. Am J Prev Med 34: 1–8
- Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D (1993) Tobacco, ethanol, coffee, pancreatitis, diabetes

results stress the need for reduction of socioeconomic differences in health.

ACKNOWLEDGEMENTS

Supported by a grant from the Dutch Cancer Society (IKZ 2000-2260).

mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 4: 375-382

- Koppert LB, Janssen-Heijnen ML, Louwman MW, Lemmens VE, Wijnhoven BP, Tilanus HW, Coebergh JW (2004) Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: a population-based study. Eur J Gastroenterol Hepatol 16: 681–688
- Lahelma E, Rahkonen O, Berg MA, Helakorp S, Prattala R, Puska P, Uutela A (1997) Changes in health status and health behavior among Finnish adults 1978–1993. Scand J Work Environ Health 23(Suppl 3): 85–90
- Lash TL, Thwin SS, Horton NJ, Guadagnoli E, Silliman RA (2003) Multiple informants: a new method to assess breast cancer patients' comorbidity. *Am J Epidemiol* 157: 249-257
- Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW (2005) Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 92: 615-623
- Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. *Eur J Cancer* **41**: 779–785
- Mackenbach JP, Stirbu I, Roskam AJ, Schaap MM, Menvielle G, Leinsalu M, Kunst AE (2008) Socioeconomic inequalities in health in 22 European countries. N Engl J Med **358**: 2468-2481
- McLaren L (2007) Socioeconomic status and obesity. Epidemiol Rev 29: 29-48
- Michels KB, Edward G, Joshipura KJ, Rosner BA, Stampfer MJ, Fuchs CS, Colditz GA, Speizer FE, Willett WC (2000) Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 92: 1740–1752
- Parazzini F, La Vecchia C, Bocciolone L, Franceschi S (1991) The epidemiology of endometrial cancer. *Gynecol Oncol* **41**: 1-16
- Pietinen P, Malila N, Virtanen M, Hartman TJ, Tangrea JA, Albanes D, Virtamo J (1999) Diet and risk of colorectal cancer in a cohort of Finnish men. *Cancer Causes Control* 10: 387–396
- Polednak AP (2006) Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. *Cancer Detect Prev* 30: 466-472
- Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW (2001) The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. *BJU Int* 87: 821-826
- Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *Br Med J* **335**: 1134
- Siemiatycki J, Krewski D, Franco E, Kaiserman M (1995) Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. *Int J Epidemiol* 24: 504-514
- Smits J, Keij I, Westert G (2001) Effecten van sociaal-economische status van kleine, middelgrote en grote geografische eenheden op de sterfte. Mndstat bevolking 11: 4-10
- Sobal J, Stunkard AJ (1989) Socioeconomic status and obesity: a review of the literature. *Psychol Bull* **105:** 260-275
- Stellman SD, Resnicow K (1997) Tobacco smoking, cancer and social class. IARC Sci Publ 229-250
- Stronks K, van de Mheen HD, Looman CW, Mackenbach JP (1997) Cultural, material, and psychosocial correlates of the socioeconomic gradient in smoking behavior among adults. Prev Med 26: 754-766
- Terry P, Giovannucci E, Michels KB, Bergkvist L, Hansen H, Holmberg L, Wolk A (2001a) Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst 93: 525-533

- Terry P, Lagergren J, Hansen H, Wolk A, Nyren O (2001b) Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. *Eur J Cancer Prev* 10: 365-369
- Tyczynski JE, Bray F, Parkin DM (2003) Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. *Lancet Oncol* **4**: 45-55
- Tzonou A, Lipworth L, Garidou A, Signorello LB, Lagiou P, Hsieh C, Trichopoulos D (1996) Diet and risk of esophageal cancer by histologic type in a low-risk population. *Int J Cancer* **68**: 300-304
- van Duijn C, Keij I (2002) Sociaal-economische status indicator op postcode niveau. Maandstatistiek van de bevolking 50: 32-35
- van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW (2005) Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 41: 1051–1057
- Voorrips LE, Goldbohm RA, van Poppel G, Sturmans F, Hermus RJ, van den Brandt PA (2000) Vegetable and fruit consumption and risks of

colon and rectal cancer in a prospective cohort study: The Netherlands Cohort Study on Diet and Cancer. *Am J Epidemiol* **152**: 1081–1092

- Wallstrom P, Wirfalt E, Janzon L, Mattisson I, Elmstahl S, Johansson U, Berglund G (2000) Fruit and vegetable consumption in relation to risk factors for cancer: a report from the Malmo Diet and Cancer Study. *Public Health Nutr* **3:** 263-271
- Wardle J, Steptoe A (2003) Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J Epidemiol Community Health 57: 440-443
- Wardle J, Waller J, Jarvis MJ (2002) Sex differences in the association of socioeconomic status with obesity. Am J Public Health 92: 1299-1304
- Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326: 455-465
- Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86: s823-s835